LB1908 / Legend Biotech 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LB1908 / Legend Biotech
NCT04467853: A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Terminated
1
34
RoW
LCAR-C18S cells
Shanghai East Hospital, Nanjing Legend Biotech Co.
Solid Tumors, Adult
07/23
07/23
LB1908-1001, NCT05539430: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Recruiting
1
56
US
LB1908
Legend Biotech USA Inc
Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
07/25
12/25

Download Options